Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) EPS (Weighted Average and Diluted) (2019 - 2025)

Bicycle Therapeutics' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.29 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 61.33% year-over-year to -$0.29; the TTM value through Dec 2025 reached -$3.16, down 9.72%, while the annual FY2025 figure was -$3.16, 8.97% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.29 in Q4 2025 per BCYC's latest filing, up from -$0.85 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.29 in Q4 2025 to a low of -$1.41 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.88, with a median of -$0.86 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 65.57% in 2022, then surged 61.33% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.61 in 2021, then crashed by 65.57% to -$1.01 in 2022, then decreased by 11.88% to -$1.13 in 2023, then skyrocketed by 33.63% to -$0.75 in 2024, then soared by 61.33% to -$0.29 in 2025.
  • Per Business Quant, the three most recent readings for BCYC's EPS (Weighted Average and Diluted) are -$0.29 (Q4 2025), -$0.85 (Q3 2025), and -$1.14 (Q2 2025).